Influence of natural and synthetic histone deacetylase inhibitors on chromatin.
CONCLUSIONS
Histone deacetylase inhibitors (HDACIs) have emerged as a new class of anticancer therapeutics. The hydroxamic acid, suberoylanilide hydroxamic acid (Vorinostat, Zolinza™), and the cyclic peptide, depsipeptide (Romidepsin, Istodax™), were approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma in 2006 and 2009, respectively. At least 15 HDACIs are currently undergoing clinical trials either alone or in combination with other therapeutic modalities for the treatment of numerous hematological and solid malignancies.


BACKGROUND
The potential utility of HDACIs has been extended to nononcologic applications, including autoimmune disorders, inflammation, diseases of the central nervous system, and malaria.


RESULTS
Given the promise of HDACIs, there is growing interest in the potential of dietary compounds that possess HDAC inhibition activity. This review is focused on the identification of and recent findings with HDACIs from dietary, medicinal plant, and microbial sources. We discuss the mechanisms of action and clinical potential of natural HDACIs.


CONCLUSIONS
Apart from identification of further HDACI compounds from dietary sources, further research will be aimed at understanding the effects on gene regulation on lifetime exposure to these compounds. Another important issue that requires clarification.
Allergy and Immune Disorders, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Paul V
PV
Licciardi
Faith A A
FA
Kwa
Katherine
K
Ververis
Natasha
N
Di Costanzo
Aneta
A
Balcerczyk
Mimi L
ML
Tang
Assam
A
El-Osta
Tom C
TC
Karagiannis
D000818:Animals; D002843:Chromatin / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans
D002843:Chromatin; D056572:Histone Deacetylase Inhibitors